AUTL
Price
$1.78
Change
-$0.07 (-3.78%)
Updated
Aug 15 closing price
Capitalization
473.73M
75 days until earnings call
ERAS
Price
$1.64
Change
+$0.07 (+4.46%)
Updated
Aug 15 closing price
Capitalization
465.22M
81 days until earnings call
Interact to see
Advertisement

AUTL vs ERAS

Header iconAUTL vs ERAS Comparison
Open Charts AUTL vs ERASBanner chart's image
Autolus Therapeutics
Price$1.78
Change-$0.07 (-3.78%)
Volume$12.16M
Capitalization473.73M
Erasca
Price$1.64
Change+$0.07 (+4.46%)
Volume$456.87K
Capitalization465.22M
AUTL vs ERAS Comparison Chart in %
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. ERAS commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (AUTL: $1.78 vs. ERAS: $1.64)
Brand notoriety: AUTL and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 608% vs. ERAS: 54%
Market capitalization -- AUTL: $473.73M vs. ERAS: $465.22M
AUTL [@Biotechnology] is valued at $473.73M. ERAS’s [@Biotechnology] market capitalization is $465.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both AUTL and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 6 TA indicator(s) are bullish while ERAS’s TA Score has 6 bullish TA indicator(s).

  • AUTL’s TA Score: 6 bullish, 5 bearish.
  • ERAS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than AUTL.

Price Growth

AUTL (@Biotechnology) experienced а -23.61% price change this week, while ERAS (@Biotechnology) price change was +17.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

AUTL is expected to report earnings on Oct 30, 2025.

ERAS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($474M) and ERAS($465M) have the same market capitalization . AUTL YTD gains are higher at: -24.255 vs. ERAS (-34.661). ERAS has higher annual earnings (EBITDA): -150.24M vs. AUTL (-226.02M). AUTL has more cash in the bank: 517M vs. ERAS (305M). ERAS has less debt than AUTL: ERAS (50.8M) vs AUTL (57.7M). AUTL has higher revenues than ERAS: AUTL (9.01M) vs ERAS (0).
AUTLERASAUTL / ERAS
Capitalization474M465M102%
EBITDA-226.02M-150.24M150%
Gain YTD-24.255-34.66170%
P/E RatioN/AN/A-
Revenue9.01M0-
Total Cash517M305M170%
Total Debt57.7M50.8M114%
FUNDAMENTALS RATINGS
AUTL: Fundamental Ratings
AUTL
OUTLOOK RATING
1..100
52
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AUTLERAS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 25 days ago
82%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASCQX17.10N/A
N/A
American Century Small Company I
NMVLX12.39N/A
N/A
Nuance Mid Cap Value Institutional
ERLVX26.79N/A
N/A
Eaton Vance Large-Cap Value R6
FIQWX17.75N/A
N/A
Fidelity Advisor Strategic Div & Inc Z
MGKQX14.54N/A
N/A
Morgan Stanley Global Permanence R6

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with OCUL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
-3.78%
OCUL - AUTL
49%
Loosely correlated
-0.24%
CRSP - AUTL
45%
Loosely correlated
+1.55%
LRMR - AUTL
44%
Loosely correlated
-5.87%
SCPH - AUTL
43%
Loosely correlated
-7.07%
ERAS - AUTL
43%
Loosely correlated
+4.46%
More